This is a China news story, published by Guardian, that relates primarily to Jacques news.
For more China news, you can click here:
more China newsFor more Jacques news, you can click here:
more Jacques newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Guardian, you can click here:
more news from GuardianOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
other chemotherapy drugs. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest chemotherapy drugs news, cancer drug news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
chemotherapy drugGuardian
•75% Informative
Jacques (Sjaak) Neefjes has been on a mission to bring back a cancer drug that hasn’t been available in Europe since 2004 .
His latest research shows that this drug, aclarubicin, can improve the survival of people with acute myeloid leukemia ( AML ) He has smuggled small amounts from China , found old samples in a Finnish freezer, and funded part of his work using an inheritance from a Dutch MP who was murdered 10 years ago .
Aclarubicin improved the five-year survival rate of AML patients by 23% compared with other chemotherapy drugs.
The next step is clinical trials, and that could pose entirely new hurdles.
The lack of a patent means that drug companies are n’t interested in financing the trials.
Another challenge is finding enough people to participate in clinical trials.
VR Score
76
Informative language
76
Neutral language
23
Article tone
semi-formal
Language
English
Language complexity
48
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
2
Source diversity
1
Affiliate links
no affiliate links